




Curriculum Vitae

1. Name, Gender, Nationality

Family Name	Name	Gender	Nationality
Alépée	Nathalie	Female	French



If you wish you can place a photograph of you here.

2. Overall Scientific Expertise

Please specify in keywords (see section 3 of your application form). If you wish you may indicate how you acquired each specific expertise (e.g. through education, in your function as..., through participation in ...).



3. Professional Experience

Professional Experience 1 (most recent)	
Occupation or position held	<i>Scientific coordinator on Alternatives Methods</i>
Date (starting)	<i>16.09.2007</i>
Date (finishing)	<i>current</i>
Main activities	<i>Coordination/Promotion/Validation of alternative methods to replace and reduce laboratory animals in toxicology testing according to the GLP regulations</i>
Main responsibilities	<i>Professional societies and affiliations: European Partnership on Alternative to Animal Testing (EPAA), The Colipa association, the French Alternative Method Initiative (GIS), IVTIP Expert committees and advisory panels: ECVAM, ICCVAM, OECD, EU FP projects Research: Eye irritation (Lead lab/ECVAM validation), Skin irritation/sensitization</i>
Name of employing organisation	<i>L'Oréal</i>
Address of employing organisation (City, Country sufficient)	<i>Aulnay sous Bois, France</i>
Type of sector	<i>Industry</i>
Professional Experience 2	
Occupation or position held	<i>Pfizer PGRD</i>
Date (starting)	<i>01.09.1998</i>
Date (finishing)	<i>15.09.2007</i>
Main activities	<i>Investigative toxicology: Global Pfizer Leader for photosafety. Leading cross functional teams such as the Immunotoxicology, Ocular, Cellular Models applied to Safety Sciences councils. Development of cell culture automation for methodologies. Development of an in vitro model to assess the pulmonary, skin, eye irritancy potential of the compounds. Drug development toxicologist support (Discovery to FIP) in Allergy and Respiratory.</i>
Main responsibilities	<i>Laboratory Manager in Investigative toxicology Representative in EPAA working groups 2 & 5 Representative in EFPIA ESAC member (peer reviewer)</i>
Name of employing organisation	<i>Pfizer Global Research and Development</i>



Address of employing organisation (City, Country sufficient)	<i>Pfizer Global Research and Development, Amboise, France</i>
Type of sector	<i>Industry</i>
Professional Experience 3	
Occupation or position held	<i>Postdoctoral Fellow</i>
Date (starting)	<i>01.03.1996</i>
Date (finishing)	<i>30.08.1998</i>
Main activities	<i>Research on function of herpes simplex virus membrane proteins in neuron infection.</i>
Main responsibilities	<i>Viral neuropathogenesis, genetic engineering of virus, neuronal culture and in vitro propagation of mutants</i>
Name of employing organisation	<i>Cambridge University, Department of pathology, UK.</i>
Address of employing organisation (City, Country sufficient)	<i>Cambridge University, UK.</i>
Type of sector	<i>Academia</i>

4. Educational Background

Educational qualification 1 (most recent)	
Description of qualification achieved	<i>Doctorat d'Université (PhD) in Medical Virology and Microbiology</i>
Principal subject / specialisation	<i>Neurology – Virology – Molecular Biology</i>
Other subjects	
Date (starting)	<i>01.09.1992</i>
Date (finishing)	<i>31.12..1995</i>
Name of organisation (incl. city and country) awarding degree	<i>CNRS (Centre National de la Recherche Scientifique) laboratory, Gif sur Yvette, France</i>
Title of degree awarded	<i>PhD</i>



Educational qualification 2

Description of qualification achieved (e.g. Bachelor of science in tissue engineering)	<i>DEA (diplôme d'étude appliquée) in Medical Virology</i>
Principal subject (e.g. Animal Physiology)	<i>Virology - Neurology - In vivo studies in rodents</i>
Other subjects	
Date (starting)	<i>01.09.1991</i>
Date (finishing)	<i>30.08.1992</i>
Name of organisation (incl. city and country) awarding degree	<i>CNRS laboratory, Gif sur Yvette, France</i>
Title of degree awarded	<i>DEA</i>

Educational qualification 3

Description of qualification achieved (e.g. Bachelor of science in tissue engineering)	<i>Master in Biochemistry, University Paris VII, France (2 years, 1990-1991)</i>
Principal subject (e.g. Animal Physiology)	<i>Biochemistry - Enzymologist</i>
Other subjects	
Date (starting)	<i>01.09.1989</i>
Date (finishing)	<i>30.08.1991</i>
Name of organisation (incl. city and country) awarding degree	<i>University Paris VII, Paris, France</i>
Title of degree awarded	<i>Master in Biochemistry</i>

Educational qualification 4

Description of qualification achieved (e.g. Bachelor of science in tissue engineering)	<i>Certificat d'Etudes Spécialisées Technologiques en Immunology</i>
Principal subject (e.g. Animal Physiology)	<i>Immunology - Molecular & Cellular methods</i>
Other subjects	
Date (starting)	<i>01.09.1988</i>
Date (finishing)	<i>30.08.1989</i>
Name of organisation (incl. city and country) awarding degree	<i>ESTBA, Paris XX, France</i>



Title of degree awarded	<i>Master in Immunology</i>
--------------------------------	-----------------------------

5. Fellowships, Awards, Membership in Learned Societies, Editorial Boards and Advisory Bodies

5.1 Fellowships

Fellowship I	
Title of fellowship	<i>European Molecular Biology Organisation (EMBO) fellowship</i>
Description of fellowship (type, maximal duration, prestige)	<i>EMBO Long term Fellowships fund and support young scientists in their pursuit of post-doctoral research to broaden their research experience, 2 years maximum</i>
Date (starting)	<i>01.01.1996</i>
Date (finishing)	<i>01.01.1998</i>
Funding/awarding organisation	<i>EMBO</i>
Address (city + country sufficient)	<i>Heidelberg, Germany</i>
Fellowship II	
Title of fellowship	<i>Cancer Research Fund (ARC) fellowship</i>
Description of fellowship (type, maximal duration, prestige)	<i>ARC Fellowship support young scientists in their research on cancer to broaden their research experience, 1 year</i>
Date (starting)	<i>01.01.1998</i>
Date (finishing)	<i>1 year</i>
Funding/awarding organisation	<i>Association pour la Recherche sur le Cancer (ARC)</i>
Address (city + country sufficient)	<i>France, http://www.arc-asso.fr/</i>



5.2 Awards

Award I	
Title of award	<i>Individual Pfizer award</i>
Description of award (type, prestige etc.)	<i>Individual Pfizer Europe achievement awards for implementation of alternatives methods</i>
Date	<i>1991</i>
Awarding organisation	<i>Pfizer</i>
Address (city + country sufficient)	<i>Sandwich, UK</i>

5.3 Membership in learned societies & professional associations & editorial boards

Society / Association / Editorial Board I	
Society / Association	<i>Colipa</i>
Description of society's / association's activities	<i>The European trade association for the cosmetic, toiletry and perfumery industry</i>
Membership from ...	<i>2008</i>
...to (if currently member, please state 'current')	<i>current</i>
Address (city + country sufficient)	<i>Brussels, Belgium</i>
Society / Association II	
Society / Association	<i>EPAA</i>
Description of society's / association's activities	<i>The European Partnership on Alternative Approaches to Animal Testing (EPAA)</i>
Membership from ...	<i>11.2005</i>
...to (if currently member, please state 'current')	<i>current</i>
Address (city + country sufficient)	<i>Brussels, Belgium</i>
Society / Association III	
Society / Association	<i>IVTIP</i>



Description of society's / association's activities	<i>European companies with an active interest in in vitro testing to be used in regulatory/safety testing or to be used in the compound discovery and development process</i>
Membership from ...	<i>2009</i>
...to (if currently member, please state 'current')	<i>current</i>
Address (city + country sufficient)	<i>Willemstad NB, The Netherlands</i>

Society / Association IV

Society / Association	<i>GIS</i>
Description of society's / association's activities	<i>Groupement d'Intérêt Français (GIS) with a cross sectorial (academia, university, SME, industry, regulation, association) interest in 3Rs in France Research and Education French Ministry</i>
Membership from ...	<i>2008</i>
...to (if currently member, please state 'current')	<i>current</i>
Address (city + country sufficient)	<i>France</i>

5.4 Membership in advisory bodies / committees

Advisory body / committee I

Name of advisory body	<i>free text</i>
Description of the roles and responsibilities of the advisory body	<i>Max. 500 characters including spaces</i>
Membership from ...	<i>DD.MM.YYYY [day.month.year]</i>
...to (if currently member, please state 'current')	<i>DD.MM.YYYY [day.month.year]</i>
Address (city + country sufficient)	<i>free text</i>



6. Publications

Excessive publication lists are not recommended. We encourage selecting, as in the application form, the 20 most relevant publications. See your publication list in section 5 of application form.

Nr.	Citation
1	<i>Scott L., Eskes C., Hoffmann S., Adriaens E., Alépée N., Bufo M., Clothier R., Facchini D., Faller C., Guest R., Harbell J., Hartung T., Kamp H., Le Varlet B., Meloni M., McNamee P., Osborne R., Pape W., Pfannenbecker U., Prinsen M., Seaman C., Spielmann H., Stokes W., Trouba K., Van den Berghe C., Van Goethem F., Vassallo M., Vinardell P., Zuang V. Bottom-up and Top-down Approach: Eye irritation testing strategy to reduce and replace in vivo studies. toxicology in vitro, in Press, 2009</i>
2	<i>C Tornier, C Amsellem, A de Brugerolle de Fraissinette, N Alépée . Assessment of the optimized SkinEthic™ Reconstructed Human Epidermis (RHE) 42 bis skin irritation protocol over 39 test substances. Toxicology in vitro in Press, 2009</i>
3	<i>N Alépée, C Tornier, C Robert, C Amsellem, M-H Roux, O Doucet, J Pachot, M Méloni, and A de Brugerolle de Fraissinette. A catch-up validation study on Reconstructed Human Epidermis (SkinEthic™ RHE) for Full Replacement of the Draize skin irritation Test. Toxicology in vitro, in press, 2009</i>
4	<i>Alépée N.; Cotovio J., Bessou-Touya S., De Wever B., Faller C., Le Varlet B., Marrec-Fairley M., Pfannenbecker U., Van Goethem F., and McNamee P. Colipa's industry pre validation program using reconstituted human corneal epithelium (SkinEthic HCE) test method for the predicting eye irritation for chemicals. Altex, in press, 2009</i>
5	<i>Bottini A., Alépée N., Phillips B., Gribaldo L., De Silva O., Hartung T., Hendrisken C., Kuil J., Pazos P., Rhein C., Schiffelers MJ., Stokes W., Theobald A., Vidal JM., Van de Sandt H., Breier S., Sintes JR., Blauaboer B. Optimisation of the post-validation process. ATLA 36, 353-366, 2008</i>
6	<i>Ahr HJ, Alépée N, Breier S, Brekelmans C, Cotgreave I, Gribaldo L, Dal Negro G, De Silva O, Hartung T, Lacerda A, Leblanc B, Lecerf C, Linge JP, Louhimies S, Manou I, Maxwell G, Müller KK, Pape W, Redhead K, Schröder KR, Sladowski D, van der Jagt K, Vanparys P. Barriers to validation: a report by the European Partnership fo Alternative Approaches to Animal Testing (EPAA) Working Group 5. Altern Lab Anim. 2008 Sep;36(4):459-64</i>
7	<i>F. Van Goethem, E. Adriaens, N. Alépée, F. Straube, B. De Wever, M. Cappadoro, S. Catoire, E. Hansen, A. Wolf, and P. Vanparys. Prevalidation of a new in vitro reconstituted human cornea model to assess the eye irritating potential of chemicals. Toxicology in vitro 20, 2006</i>
8	<i>S. Catoire, N. Alépée, MT. Masson, MC Bonnet and S. Chevalier. Evaluation d'un nouveau model in vitro de cornée humaine comme alternative au test in vivo. Biotechnocentre 37, 2003.</i>
9	<i>A. Flamand, T. Bennardo, N. Babic-Alépée, BG. Klupp, and TC. Mettenleiter. The absence of glycoprotein gL, but not gC or gK, severely impairs pseudorabies virus neuroinvasiveness. J Virol. 75(22), 2001.</i>



10	<i>Babic-Alépée N., Rodger G., Arthur J. and Minson A.C. A study of primary neuronal infection by mutants of herpes simplex virus type 1 lacking dispensable and non-dispensable glycoproteins. J. Gen. Virol. 80, 2403-2409, 1999</i>
11	<i>Babic-Alépée N. Bases moléculaires du neurotropisme du virus de la Pseudorange. Séminaire Fondamental de Microbiologie Clinique des Laboratoires Merck Sharp & Dohme-Chibret. 1999</i>
12	<i>Flamand A., Babic N. and Coulon P. Bases moléculaires du neurotropisme viral (Rage et Pseudo-rage). Virologie 2, 52-66, 1998</i>
13	<i>Babic N., Klupp B., Makoschey B, Karger A., Flamand A. and Mettenleiter T. Glycoprotein gH of PrV is essential for penetration and propagation in cell culture and in the nervous system of mice. J. gen. Virol. 77, 2277-2285, 1996</i>
14	<i>Babic N., Klupp B., Brack A., Mettenleiter T., Ugolini G. and Flamand A. Deletion of glycoprotein gE reduces the propagation of PrV in the nervous system of mice after intranasal inoculation. Virology, 219, 279-284, 1996</i>
15	<i>Babic N., Mettenleiter T., Ugolini G., Flamand A. and Coulon P. Propagation of PrV in the nervous system of the mouse after intranasal inoculation. Virology, 204, 616-625, 1994</i>
16	<i>Babic N., Mettenleiter T., Flamand A. and Ugolini G. Role of the essential glycoproteins gII and gp50 in the transneuronal transfer of PrV from the hypoglossal nerves of mice. J. Virol. 67, 4421-4426, 1993</i>